Table 3.
Course of Treatment, RDI, OSAS, BMI, and IGF-1 Levels in Individual Patients
| Course of Individual Patients | Baseline—T0 | 1 Year—T1 | 2.5 Years—T2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Sex | Treatment | RDI | OSAS | BMI | IGF-1 | RDI | OSAS | BMI | IGF-1 | RDI | OSAS | BMI | IGF-1 |
| 1 | M | MS (0-6) + S: cured | 46.3 | + | 31.1 | 208 | 17.9 | + | 29.4 | O | 14.2 | - | 30.7 | 13 |
| 2 | M | MS (0-6) + S: cured | 24.2 | + | 24.9 | 80.7 | 3.8 | - | 25.6 | 34.8 | 5.1 | - | 24 | 28 |
| 3 | M | MS (0-6) + S: cured | 35.2 | + | 25.6 | 111 | 6.6 | + | 24.8 | O | 5.6 | - | 24.7 | 29.8 |
| 4 | M | MS (0-7) + S: cured | 54.6 | + | 24.6 | 61.9 | 95 | + | 25 | 25.1 | 8.4 | + | 24.8 | 29.4 |
| 5 | M | MS (0-6) + S: cured | 26.9 | + | 28.1 | 66.7 | 11.6 | + | 28 | 8.5 | 14.1 | - | 28.7 | 34.1 |
| 6 | F | MS (0-6) + S: cured | 32.5 | + | 23.5 | 108 | 14.1 | + | 23.1 | 23.6 | 7.9 | - | 22.5 | 18.2 |
| 7 | F | MS (0-6) + S: cured | 17.6 | + | 30.7 | 77.2 | 6.1 | - | 30.5 | 20.4 | 0.4 | - | 31.5 | 22.4 |
| 8 | F | MS (0-6) + S: cured | 27.9 | + | 27.5 | 97.3 | 15.7 | + | 34.6 | 23.5 | 1.2 | - | 28.5 | 25.5 |
| 9 | F | MS (0-6) + S: RD | 12.1 | + | 32.3 | 79.8 | 3 | - | 33.3 | 36.5 | 1.3 | - | 31.4 | 28.3 |
| MS (14-30): BC (16-30) | ||||||||||||||
| 10 | F | MS (0-8) + S: cured | 99.2 | + | 32.6 | 80.1 | 3.9 | - | 35.5 | 19.3 | 5.9 | - | 35 | 10.2 |
| 11 | M | S (2): cured | 5.5 | - | 28.7 | 122.1 | 13.4 | - | 25.5 | 34.2 | 7.2 | - | 26.1 | 30.4 |
| 12 | F | Primary MS (0-30): BC (6-30) | 6.2 | - | 25.7 | 40.6 | 1.9 | - | 26.5 | 24.7 | 14.4 | - | 26.8 | 28 |
| 13 | F | MS (0-6) + S: RD | 1.2 | - | 21.2 | 83.7 | 4 | - | 21.7 | 48.3 | 0 | - | 20.1 | 17.8 |
| MS (13-30): BC (15-30) | ||||||||||||||
| 14 | F | MS (0-6) + S: cured | 7.1 | - | 21.3 | 63.8 | 18.1 | + | 21.2 | 11 | 4.6 | - | 22 | 11.7 |
| 15 | F | MS (0-6) + S: RD | 3.1 | - | 32.6 | 118.7 | 3.7 | - | 37.5 | 54.4 | 1.3 | - | 38.4 | 25.8 |
| MS (12-24) + MP (15-22) + reS (24): cured | ||||||||||||||
| 16 | M | MS (0-6) + S: RD | 77.4 | + | 26.4 | 109.5 | 70.3 | + | 28.2 | 27.4 | 24.1 | + | 26.7 | 20.3 |
| MS (11-30): BC (12-30) | ||||||||||||||
| 17 | F | MS (0-6) S: RD | 20.9 | + | 29.1 | 146 | O | O | 27.6 | 83.2 | 9.7 | - | 28 | 25.9 |
| MS (8-30) + MP (11-30) + SRT (20-21): BC (29-30) | ||||||||||||||
| 18 | M | S (1.5): RD | 35.9 | + | 30.2 | 132.5 | 13.9 | + | 29.7 | 40.7 | 8.6 | - | 29.1 | 28 |
| MS (2.5-30): BC (14-30) | ||||||||||||||
| 19 | F | MS (0-11) + S: cured | 2.2 | - | 25.8 | 53.5 | 2.6 | - | 26.3 | 17.2 | 9.1 | - | 27 | 15.6 |
| 20 | F | MS (0-6) + S: RD | 5.2 | - | 27.5 | 85.2 | O | O | 24.6 | 20.2 | 2.4 | - | 25 | 21.1 |
| MS (8-30): BC (10-30) | ||||||||||||||
| 21 | M | MS + MD (0-6) + S: RD | Oa | + | 36.2 | 95.7 | 3.6 | - | 38.4 | 34.9 | 23.7 | + | 30.3 | 34 |
| MS + MD (14-30): BC (24-30) | ||||||||||||||
| 22 | M | MS (0-6) + MP (4-6) + S: RD | 13.3 | + | 33.1 | 114.2 | 0.2 | - | 34.3 | 45.9 | O | O | 30.4 | 27 |
| MS (9-30) + MP (10-30) + GRS (12): BC (15-30) | ||||||||||||||
| 23 | M | MS (0-6) + S: cured | 28 | + | 31.6 | 130.4 | 35.4 | + | 30.5 | 40.3 | 24.1 | + | 28.8 | 21.9 |
| 24 | F | MS (0-6) + S: cured | 23.8 | + | 25.6 | 105.8 | 26.7 | + | 26.9 | 31.6 | O | O | 26.4 | 28.7 |
| 25 | M | MS (0-5) + S: cured | 47.3 | + | 34.3 | 145.4 | 16.1 | + | 35 | 20.6 | O | O | 31.1 | 33 |
| 26 | F | Lost to follow-up | 7.9 | + | 30.8 | 84.5 | Lost to follow-up | Lost to follow-up | ||||||
| 27 | F | Primary MS (0-30) + MP (9-30): BC (22-30) | 15.2 | + | 35.1 | 84.6 | 24.3 | + | 43.1 | 36.1 | 5.2 | + | 41 | 19.3 |
| Patients with OSAS | 20 (74.1%) | 13 (54.2%) | 5 (21.7%) | |||||||||||
In patients with medical pretreatment, surgery and cessation of medical treatment took place simultaneously. The moment or timespan of treatment in months is displayed between parentheses. In the OSAS column, a ‘+’ means that OSAS is present, a ‘-’ means that OSAS is absent. Abbreviations: O, data not available; M, medical treatment; MS, medical treatment with a somatostatin analogue (SSA); MP, medical treatment with pegvisomant (PEGV); MD, medical treatment with a dopamine agonist; MS + MP, medical treatment with SSA combined with PEGV; MS + MD, medical treatment SSA combined with a dopamine agonist; S, surgery; SRT: stereotactic radiotherapy; GRS, gammaknife radiosurgery; BC, biochemical control with use of medication; Re-s, second surgical procedure; RD, residual or recurrent disease; AHI, apnea hypopnea index; BMI, body mass index in kg/m2; ESS, Epworth Sleepiness Scale; GH, growth hormone; IGF-1, insulin-like growth factor 1; LSaO2, lowest oxygen saturation; NA, not applicable; ODI, oxygen desaturation index; OSAS, obstructive sleep apnea syndrome; RDI, respiratory disturbance index. aThe baseline PSG of this patient was of insufficient quality to calculate RDI or AHI, but he had an oxygen desaturation index (ODI) of 80/hour and has been diagnosed with severe OSAS prior to study participation.